Aim immunotech reports third quarter 2023 financial results and provides clinical pipeline update

– highlights continued execution across ampligen® clinical development programs – company is well positioned to achieve multiple value-driving milestones during remainder of 2023 and 2024 – will host conference call and webcast today, november 15 th at 8:30 am et ocala, fla., nov. 15, 2023 (globe newswire) -- aim immunotech inc. (nyse american: aim) (“aim” or the “company”) today reported financial results for the third quarter 2023 and provided a business update.
AIM Ratings Summary
AIM Quant Ranking